We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Roche’s Tecentriq Improves Disease-Free Survival of Lung Cancer Patients in Phase 3 Trial
Roche’s Tecentriq Improves Disease-Free Survival of Lung Cancer Patients in Phase 3 Trial
Roche’s blockbuster oncology drug Tecentriq (atezolizumab) met its primary endpoint of disease-free survival in its phase 3 lung cancer study evaluating the drug as an adjuvant therapy, according to an interim analysis.